Index RUT P/E - EPS (ttm) -2.88 Insider Own 0.91% Shs Outstand 82.73M Perf Week -26.34%
Market Cap 125.30M Forward P/E - EPS next Y -1.06 Insider Trans -3.30% Shs Float 82.23M Perf Month 25.83%
Income -237.09M PEG - EPS next Q -0.56 Inst Own 62.52% Short Float 16.74% Perf Quarter -29.44%
Sales 32.31M P/S 3.88 EPS this Y 50.77% Inst Trans -6.86% Short Ratio 3.19 Perf Half Y -56.98%
Book/sh 1.62 P/B 0.93 EPS next Y 25.07% ROA -56.40% Short Interest 13.77M Perf Year -83.52%
Cash/sh 3.25 P/C 0.46 EPS next 5Y 23.95% ROE -98.10% 52W Range 1.12 - 9.08 Perf YTD 18.90%
Dividend Est. - P/FCF - EPS past 5Y -1.48% ROI -153.31% 52W High -83.37% Beta 2.08
Dividend TTM - Quick Ratio 3.75 Sales past 5Y 96.99% Gross Margin 82.02% 52W Low 34.82% ATR (14) 0.27
Dividend Ex-Date - Current Ratio 3.75 EPS Y/Y TTM -40.05% Oper. Margin -739.40% RSI (14) 46.12 Volatility 12.82% 19.49%
Employees 246 Debt/Eq 0.26 Sales Y/Y TTM -58.64% Profit Margin -733.74% Recom 2.60 Target Price 3.78
Option/Short Yes / Yes LT Debt/Eq 0.15 EPS Q/Q -138.92% Payout - Rel Volume 0.41 Prev Close 1.47
Sales Surprise 2.85% EPS Surprise -45.73% Sales Q/Q -49.03% Earnings Mar 05 AMC Avg Volume 4.32M Price 1.51
SMA20 -15.64% SMA50 1.15% SMA200 -53.12% Trades
Volume 1,753,378 Change 2.72%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-16-24 Downgrade JP Morgan
Neutral → Underweight
Dec-13-24 Downgrade Truist
Buy → Hold
Dec-13-24 Downgrade Stifel
Buy → Hold
$11 → $3
Dec-13-24 Downgrade Chardan Capital Markets
Buy → Neutral
Dec-11-24 Downgrade Wells Fargo
Overweight → Equal Weight
$7 → $4
Nov-25-24 Downgrade BofA Securities
Buy → Underperform
$13 → $1
Nov-06-24 Upgrade Evercore ISI
In-line → Outperform
Nov-04-24 Downgrade Raymond James
Outperform → Mkt Perform
Aug-08-24 Upgrade BofA Securities
Neutral → Buy
$13 → $15
May-09-24 Upgrade Morgan Stanley
Underweight → Equal-Weight
$7
Oct-24-23 Upgrade Citigroup
Neutral → Buy
$11
Oct-18-23 Upgrade JP Morgan
Underweight → Neutral
$8
Oct-17-23 Downgrade Cantor Fitzgerald
Overweight → Neutral
Sep-29-23 Upgrade Stifel
Hold → Buy
$9 → $17
Jun-12-23 Upgrade Raymond James
Mkt Perform → Outperform
$17
Feb-01-23 Initiated Cantor Fitzgerald
Overweight
$15
Dec-13-22 Initiated Citigroup
Neutral
$11
Dec-06-22 Resumed Credit Suisse
Neutral
$13
Nov-18-22 Downgrade Oppenheimer
Outperform → Perform
$28 → $12
Nov-18-22 Downgrade Credit Suisse
Outperform → Neutral
$25 → $13
Show Previous Ratings
Mar-05-25 05:25PM
04:19PM
(Associated Press Finance)
04:05PM
Feb-24-25 09:00AM
Jan-14-25 09:30AM
09:00AM
Loading…
Jan-13-25 09:00AM
Jan-06-25 09:00AM
Dec-30-24 03:11PM
Dec-14-24 07:01AM
Dec-13-24 02:15PM
01:26PM
06:44AM
Dec-12-24 04:00PM
12:37PM
Dec-09-24 12:00PM
11:30AM
Loading…
Dec-04-24 11:30AM
Nov-26-24 06:50AM
Nov-06-24 09:00AM
Nov-05-24 01:59PM
Nov-04-24 08:40AM
07:36AM
(Associated Press Finance)
07:30AM
Oct-31-24 03:55AM
Oct-25-24 10:00AM
Oct-22-24 12:13PM
(Pharmaceutical Technology) -12.50%
07:15AM
07:00AM
Oct-21-24 04:30PM
Oct-18-24 04:01PM
Oct-17-24 05:01PM
06:27AM
Loading…
Oct-05-24 06:27AM
Oct-04-24 07:13PM
(Pharmaceutical Technology) +5.62%
-5.03%
07:33AM
Oct-03-24 06:00PM
Sep-06-24 11:31AM
Aug-28-24 09:00AM
Aug-08-24 09:33AM
03:39AM
(Thomson Reuters StreetEvents)
Aug-07-24 08:05AM
07:07AM
(Associated Press Finance)
07:00AM
Jul-31-24 07:00AM
Jul-17-24 11:30AM
Jul-09-24 07:59AM
Jul-08-24 09:00AM
Jun-29-24 08:40PM
06:30PM
Jun-27-24 09:04AM
Jun-26-24 09:33PM
04:36PM
Jun-25-24 08:00AM
Jun-17-24 08:13AM
Jun-14-24 03:01AM
03:00AM
Jun-07-24 11:30AM
May-22-24 07:05PM
May-14-24 07:01PM
04:27PM
10:00AM
May-10-24 06:00AM
May-09-24 03:38PM
01:12PM
12:40PM
11:33AM
08:00AM
May-08-24 10:33PM
(Thomson Reuters StreetEvents) -11.36%
11:55AM
08:25AM
07:29AM
(Associated Press Finance)
07:00AM
May-02-24 07:00AM
May-01-24 10:46AM
08:00AM
Apr-29-24 10:26AM
Apr-26-24 10:00AM
Apr-22-24 04:31PM
Mar-29-24 11:30AM
Mar-07-24 03:31AM
Mar-05-24 11:52PM
Mar-04-24 10:30AM
Mar-02-24 09:49PM
Feb-29-24 11:26AM
08:42AM
Feb-28-24 11:15PM
(Thomson Reuters StreetEvents) +24.94%
08:10AM
07:35AM
07:08AM
(Associated Press Finance)
07:00AM
Feb-21-24 07:00AM
Feb-19-24 09:55AM
Feb-10-24 05:09PM
Feb-06-24 12:00PM
Jan-31-24 09:00AM
Jan-28-24 08:45AM
Jan-21-24 09:37AM
Jan-17-24 12:04PM
Jan-15-24 05:19AM
Jan-11-24 04:38PM
Jan-08-24 08:15AM
07:45AM
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lucera Erick EVP, CHIEF FINANCIAL OFFICER Mar 04 '25 Sale 1.71 4,109 7,030 112,720 Mar 05 04:44 PM O'Neill Gilmore Neil CEO Mar 04 '25 Sale 1.71 16,632 28,452 295,474 Mar 05 04:43 PM Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Mar 04 '25 Sale 1.71 2,891 4,946 70,245 Mar 05 04:41 PM O'Neill Gilmore Neil Officer Mar 03 '25 Proposed Sale 1.86 35,000 65,100 Feb 28 04:40 PM Lucera Erick Officer Mar 03 '25 Proposed Sale 1.86 8,000 14,880 Feb 28 04:39 PM Burkly Linda Officer Mar 03 '25 Proposed Sale 1.86 6,000 11,160 Feb 28 04:35 PM O'Neill Gilmore Neil CEO Dec 03 '24 Sale 2.08 1,618 3,361 312,106 Dec 05 04:40 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Dec 03 '24 Sale 2.08 541 1,124 133,354 Dec 05 04:37 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Sep 04 '24 Sale 3.42 518 1,774 133,895 Sep 06 04:20 PM O'Neill Gilmore Neil CEO Sep 04 '24 Sale 3.42 1,555 5,325 313,724 Sep 06 04:18 PM O'Neill Gilmore Neil Officer Sep 03 '24 Proposed Sale 3.92 3,000 11,760 Aug 29 04:19 PM Mei Baisong Officer Sep 03 '24 Proposed Sale 3.92 1,000 3,920 Aug 29 04:17 PM Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Jul 25 '24 Sale 5.42 11,886 64,370 73,136 Jul 26 05:02 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Jul 19 '24 Sale 5.21 6,619 34,456 134,413 Jul 22 05:01 PM O'Neill Gilmore Neil CEO Jun 04 '24 Sale 5.50 12,191 66,997 315,279 Jun 06 04:17 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Jun 04 '24 Sale 5.50 511 2,808 141,032 Jun 06 04:16 PM Lucera Erick EVP, CHIEF FINANCIAL OFFICER May 20 '24 Sale 5.61 22,337 125,404 116,829 May 22 04:30 PM Hopfield Jessica Director May 13 '24 Buy 5.64 45,000 253,868 67,700 May 14 04:17 PM
Index - P/E - EPS (ttm) -1.05 Insider Own 11.75% Shs Outstand 88.28M Perf Week -9.16%
Market Cap 22.51M Forward P/E - EPS next Y -0.37 Insider Trans 39.92% Shs Float 77.91M Perf Month -41.74%
Income -52.30M PEG - EPS next Q -0.12 Inst Own 23.12% Short Float 1.96% Perf Quarter -47.75%
Sales 3.02M P/S 7.45 EPS this Y 59.23% Inst Trans 69.69% Short Ratio 0.93 Perf Half Y -36.09%
Book/sh 0.24 P/B 1.07 EPS next Y 49.60% ROA -121.55% Short Interest 1.53M Perf Year -85.51%
Cash/sh 0.13 P/C 2.01 EPS next 5Y 45.66% ROE -271.97% 52W Range 0.24 - 1.78 Perf YTD -28.87%
Dividend Est. - P/FCF - EPS past 5Y -18.68% ROI -187.31% 52W High -85.67% Beta 0.19
Dividend TTM - Quick Ratio 3.12 Sales past 5Y -43.84% Gross Margin -70.96% 52W Low 6.25% ATR (14) 0.04
Dividend Ex-Date - Current Ratio 3.56 EPS Y/Y TTM 50.14% Oper. Margin -1653.95% RSI (14) 33.71 Volatility 9.99% 12.59%
Employees 107 Debt/Eq 0.61 Sales Y/Y TTM 338.75% Profit Margin -1730.00% Recom 1.40 Target Price 2.25
Option/Short Yes / Yes LT Debt/Eq 0.58 EPS Q/Q 70.38% Payout - Rel Volume 0.32 Prev Close 0.25
Sales Surprise 14.54% EPS Surprise 5.90% Sales Q/Q 174.17% Earnings Feb 10 AMC Avg Volume 1.64M Price 0.25
SMA20 -17.42% SMA50 -28.87% SMA200 -51.13% Trades
Volume 524,526 Change 1.23%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-25-24 Downgrade BTIG Research
Buy → Neutral
Jul-28-23 Initiated Piper Sandler
Overweight
$10
Jun-15-23 Initiated BTIG Research
Buy
$15
Apr-28-21 Initiated Truist
Buy
$12
Oct-22-19 Initiated Oppenheimer
Outperform
$9
Mar-11-25 07:30AM
Mar-06-25 04:05PM
Feb-10-25 04:05PM
(GlobeNewswire) +5.37%
-6.49%
Feb-07-25 07:10AM
Feb-05-25 09:29AM
04:05PM
Loading…
Jan-27-25 04:05PM
Jan-24-25 09:15AM
Jan-06-25 08:00AM
Dec-03-24 04:05PM
(GlobeNewswire) +7.85%
-8.67%
Dec-02-24 07:30AM
Nov-26-24 07:30AM
Nov-14-24 04:05PM
(GlobeNewswire) +9.71%
-5.38%
Nov-11-24 04:05PM
07:00AM
Nov-08-24 07:06AM
04:22PM
Loading…
Oct-29-24 04:22PM
(GlobeNewswire) +11.65%
+8.78%
Oct-07-24 07:00AM
Oct-02-24 07:30AM
Sep-28-24 07:40AM
07:35AM
Sep-27-24 07:34AM
07:32AM
07:30AM
Sep-23-24 08:00AM
Aug-06-24 04:05PM
Jul-31-24 04:15PM
Jul-23-24 04:05PM
Jul-16-24 04:05PM
Jul-10-24 09:55AM
Jun-26-24 08:01AM
10:31AM
Loading…
Jun-25-24 10:31AM
08:28AM
07:37AM
Jun-24-24 08:53PM
05:25PM
04:15PM
Jun-13-24 04:05PM
Jun-03-24 07:00AM
May-23-24 04:09PM
May-01-24 07:00AM
Mar-21-24 12:00PM
Mar-20-24 09:00AM
Feb-13-24 08:51AM
Feb-12-24 04:05PM
Jan-18-24 08:00AM
Dec-27-23 07:30AM
Dec-21-23 01:40AM
Nov-15-23 04:05PM
(GlobeNewswire) +23.57%
-8.96%
Nov-14-23 10:00AM
Nov-13-23 04:05PM
Nov-03-23 12:00PM
Oct-19-23 04:05PM
Oct-17-23 04:05PM
(GlobeNewswire) +8.48%
-6.17%
07:30AM
Oct-16-23 07:30AM
07:00AM
Oct-04-23 07:30AM
Oct-02-23 04:05PM
Sep-27-23 09:00AM
Sep-18-23 04:05PM
(GlobeNewswire) -7.95%
+6.83%
Sep-07-23 07:30AM
Sep-06-23 07:00AM
Aug-10-23 04:05PM
Aug-08-23 09:55AM
Aug-07-23 04:05PM
Aug-01-23 04:05PM
Jul-28-23 10:13AM
Jul-24-23 04:05PM
(GlobeNewswire) -6.11%
-5.42%
Jun-22-23 04:05PM
Jun-15-23 04:10PM
04:05PM
Jun-09-23 06:34AM
Jun-08-23 06:43AM
Jun-07-23 08:25AM
Jun-06-23 06:34AM
Jun-05-23 06:44AM
Jun-02-23 06:56AM
Jun-01-23 06:29AM
May-31-23 06:40AM
May-30-23 06:50AM
May-26-23 06:59AM
May-25-23 06:38AM
May-24-23 06:43AM
May-23-23 06:33AM
May-22-23 07:49AM
May-19-23 07:03AM
May-18-23 06:39AM
May-17-23 06:35AM
May-16-23 04:05PM
Apr-19-23 09:00AM
Mar-31-23 06:36AM
Mar-23-23 04:05PM
Mar-14-23 04:35PM
Mar-10-23 07:04AM
Feb-22-23 07:00AM
Feb-09-23 04:05PM
(GlobeNewswire) -6.21%
-7.83%
Jan-30-23 07:00AM
Jan-24-23 04:05PM
Jan-17-23 04:05PM
Dec-13-22 09:25AM
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gaul Michael A. Chief Operating Officer Feb 19 '25 Buy 0.38 6,000 2,294 94,150 Feb 21 05:00 PM Carey Robert Director Sep 26 '24 Buy 0.50 1,476,626 744,662 1,476,626 Oct 01 09:58 PM Lisi Steven A. CEO and Chairman of the Board Sep 26 '24 Buy 0.50 1,476,626 744,662 3,249,411 Oct 01 09:27 PM Avniel Amir Officer Aug 22 '24 Proposed Sale 0.46 180,415 83,442 Aug 22 10:13 AM Lisi Steven A. CEO and Chairman of the Board Aug 15 '24 Buy 0.37 50,000 18,340 1,772,785 Aug 19 06:06 AM Lucera Erick Director Aug 14 '24 Buy 0.40 39,266 15,565 43,608 Aug 15 05:09 PM Carey Robert Director Aug 14 '24 Buy 0.40 100,000 39,680 3,076,864 Aug 15 05:09 PM Lisi Steven A. CEO and Chairman of the Board Aug 14 '24 Buy 0.39 100,000 38,640 1,722,785 Aug 15 05:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
